Skip to main content

Table 1 The pathways of lncRNA-H19 in atherosclerosis-related pathophysiological processes

From: Long non-coding RNA H19 in atherosclerosis: what role?

Pathway Function Experiment Experimental Material Ref.
lncRNA-H19/CTCF/PKD1 pro-angiogenesis in vivo aortic tissues from ApoE−/− knockout mice (Yang et al. 2019)
lncRNA-H19/miR-199a-5p/VEGF-A, pro-angiogenesis in vitro BMSCs from mice (Hou et al. 2018)
lncRNA-H19/miR-29a/VEGF-A, pro-angiogenesis in vitro glioma tissue specimens from patients diagnosed with glioma undergoing surgical resection, human brain microvascular endothelial cell line (Jia et al. 2016)
lncRNA-H19/miR-29c/VEGF-A pro-angiogenesis in vitro and in vivo vascularized corneas from patients, rat model of CNV, HUVECs (Sun et al. 2019a)
lncRNA-H19/miR-181a/eNOS/VEGF pro-angiogenesis in vitro HMEC-1 cells (Zhu et al. 2019a)
lncRNA-H19/EZH2/VASH1 pro-angiogenesis in vitro and in vivo subcutaneous model in nude mice, HAMSCs, HUVECs (Yuan et al. 2019)
lncRNA-H19/STAT3 pro-angiogenesis in vitro, in vivo and ex vivo carotid plaques from patients, endothelial-specific inducible lncRNA-H19 deficient mice and control littermates, aortic rings from young and aged mice, monocytes, HUVECs, hCoAECs (Hofmann et al. 2019)
lncRNA-H19/miR-675/Class II HDAC anti-adipogenic in vitro BMSCs from human (Huang et al. 2016)
lncRNA-H19/miR-188/LCoR anti-adipogenic in vitro BMSCs from mice (Wang et al. 2018)
lncRNA-H19/miR-130a/PPARγ pro-lipid accumulation in vitro and in vivo mouse model of NFALD, HepG2 and Huh-7 cells for NAFLD cellular model (Liu et al. 2019)
lncRNA-H19/PTBP1/SREBP1c pro-lipid accumulation in vitro and in vivo human liver specimens, lncRNA-H19-deleted mice, lncRNA-H19 overexpressed and PTBP1 knockdown mice, primary hepatocytes from mice (Liu et al. 2018)
lncRNA-H19/MBD1/PEGs pro-adipogenic, anti-lipid accumulation in vitro and in vivo adipose tissues from mice exposed cold or exposed to chronic HFD feeding, PIBA cell line (Schmidt et al. 2018)
lncRNA-H19/miR-130b pro-lipid accumulation, pro-inflammatory in vitro blood samples from atherosclerotic patients and non-atherosclerotic patients, mouse macrophages cell line (Raw264.7) (Han et al. 2018)
lncRNA-H19/p38&p65/NF-κB pro-inflammatory in vitro blood samples from atherosclerotic patients and healthy volunteers, atherosclerotic plaque and adjacent tissues from ApoE−/− mice, VSMCs, HUVECs (Pan 2017)
in vitro blood samples from atherosclerotic patients and healthy volunteers, HUVECs (Li et al. 2019a)
lncRNA-H19/let-7a/IL-6 pro-inflammatory in vivo and ex vivo human AAA samples and adjacent normal aortic tissues, mouse model of AAA, ApoE−/− mice, mouse aortic VSMCs, mouse macrophages cell line (Raw264.7) (Sun et al. 2019b)
lncRNA-H19/let-7/periostin pro-inflammatory in vitro HUVECs (Cao et al. 2019)
lncRNA-H19/ACP5 pro-proliferation, anti-apoptosis in vitro and in vivo blood samples from atherosclerotic patients and healthy subjects, mouse model of ischemic stroke, VSMCs, HUVECs (Huang et al. 2019)
lncRNA-H19/let-7a/cyclin D1 pro-proliferation in vitro and in vivo common carotid arteries from rat model of carotid artery balloon injury, HA-VSMCs, HEK 293 T cells (Sun et al. 2019c)
lncRNA-H19/let-7b/AT1R pro-proliferation in vitro and in vivo Serum, lung tissues and PAMSCs from rat/mouse model of PAH (Su et al. 2018)
lncRNA-H19/miR-148b/WNT/β-catenin pro-proliferation, anti-apoptosis in vitro blood samples from atherosclerotic patient without any treatment and healthy volunteers, HA-VSMCs (Zhang et al. 2018a)
lncRNA-H19/miR-675/PTEN pro-proliferation in vitro and in vivo common carotid arteries from rat model of carotid artery balloon injury, HA-VSMCs, HEK 293 T cells (Lv et al. 2018)
lncRNA-H19/miR-675-5p/Mfn2 pro-proliferation, anti-apoptosis in vitro and in vivo vascular walls from rat model of carotid artery balloon injury, VSMCs (Xu and Sun 2018)
lncRNA-H19/HIF1α/Mdm2/p53/Bcl-2&BAX pro-apoptosis in vitro and in vivo AAA samples from patients and abdominal aortic samples from organ donor controls, mouse model of AAA, mini-pigs model of AAA, HA-VSMCs (Li et al. 2018)
lncRNA-H19/miR-22-3p/KDM3A alleviate MI in vitro and in vivo rat model of AMI, neonatal rat cardiomyocytes (Zhang et al. 2020)
lncRNA-H19/miR-139/Sox8 alleviate MI in vitro rat embryonic cardiomyocyte cell line (H9C2) (Gong et al. 2017)
lncRNA-H19/YB-1 aggravate cardiac remodeling after infarction in vitro and in vivo mouse model of MI, cardiomyocytes and cardiac fibroblasts from MI mice, mouse embryonic fibroblast cell line (NIH3T3) (Choong et al. 2019)
lncRNA-H19/miR-877-3p/Bcl-2 alleviate myocardial I/R in vitro and in vivo mouse model of myocardial I/R injury, NMVCs (Li et al. 2019b)
lncRNA-H19/miR-103&miR-107/FADD alleviate myocardial I/R in vitro and in vivo mouse model of myocardial I/R injury, rat embryonic cardiomyocyte cell line (H9C2) (Wang et al. 2015)
lncRNA-H19/nucleolin alleviate myocardial I/R in vitro and in vivo mouse model of myocardial IP and I/R injury, rat embryonic cardiomyocyte cell line (H9C2), neonatal rat cardiomyocytes (Chen et al. 2020)
lncRNA-H19/miR-29b-3p/cIAP1 alleviate myocardial I/R in vitro neonatal rat cardiomyocytes, rat embryonic cardiomyocyte cell line (H9C2), HEK 293 T cells (Zhang et al. 2019)
lncRNA-H19/miR-675/PPARα aggravate myocardial I/R in vitro and in vivo mouse model of myocardial I/R injury, neonatal mouse cardiomyocytes (Luo et al. 2019)
  1. Abbreviations: lncRNAs long non-coding RNAs, miRNAs microRNAs, CTCF CCCTC-binding factor, PKD1 Polycystic kidney disease 1, ApoE Apolipoprotein E, VEGF Vascular endothelial growth factor, BMSCs Bone marrow mesenchymal stem cells, CNV Corneal neovascularization, HUVECs Human umbilical vein endothelial cells, eNOS endothelial NO synthase, HMEC-1 Human dermal vascular endothelial cells, EZH2 Enhancer of zeste homolog 2, VASH1 Vasohibin1, HAMSCs Human amniotic mesenchymal stem cells, STAT3 Signal transducer and activator of transcription 3, hCoAEC human coronary artery endothelial cells, Class II HDAC Class II histone deacetylase, LCoR Ligand-dependent corepressor, PPARγ Peroxisome proliferator-activated receptor γ, NFALD Nonalcoholic fatty liver disease, PTBP1 Polypyrimidine tract-binding protein 1, SREBP1c Sterol regulatory element-binding protein 1c, MBD1 Methyl-CpG–binding domain protein 1, HFD High-fat diet, PIBA Primary immortalized brown adipocytes, NF-κB Nuclear factor-κB, VSMCs Vascular smooth muscle cells, IL-6 Interleukin-6, AAA Abdominal aortic aneurysm, ACP5 Acid phosphatase 5, HA-VSMCs Human aortic vascular smooth muscle cells, HEK Human embryonic kidney, AT1R Ang II type 1 receptor, PASMCs Pulmonary arterial smooth muscle cells, PAH Pulmonary arterial hypertension, PTEN Phosphatase and tensin homology deleted on chromosome ten, Mfn2 Mitofusin-2, HIF1α Hypoxia-inducible factor 1α, Mdm2 Mouse double minute 2 homolog, Bcl-2 B cell lymphoma 2, BAX Bcl-2 associated X, KDM3A Lysine (K)-specific demethylase 3A, MI Myocardial infarction, AMI Acute myocardial infarction, Sox8 Sex determining region Y (SRY)-related high-mobility group box 8, YB-1 Y-box-binding protein-1, I/R Ischemia/reperfusion, NMVCs Neonatal mouse ventricular cells, FADD Fas-associated protein with death domain, IP Ischemic preconditioning, cIAP1 cellular inhibitor of apoptosis protein 1, PPARα Peroxisome proliferator-activated receptor α